Table 3.
Risk factors for per-patient clearance with TCA therapy
| Covariate | Proportion showing complete clearance (percent) | Univariate analysis | Analysis adjusting for HIV status only | |||||
|---|---|---|---|---|---|---|---|---|
| Odds ratio | 95% confidence interval | p-value | Adjusted Covariate Odds ratio | 95% confidence interval | p-value | |||
| Age | <40 | 9/20 (45) | 5.3 | 0.8–58 | 0.13 | 6.1 | 0.8–67.6 | 0.09 |
| 41–48 | 10/20 (50) | 7.2 | 1.1–77 | 0.07 | 8.4 | 1.1–94 | 0.04 | |
| >49 | 2/14 (14) | 1.0 | 1.0 | |||||
|
| ||||||||
| Race | White | 11/34 (32) | 0.5 | 0.1–2.0 | 0.32 | 0.5 | 0.1–1.8 | 0.36 |
| Other | 10/20 (50) | 1.0 | 1.0 | |||||
|
| ||||||||
| Grade of anal lesion | AIN 2–3 1 | 9/28 (32) | 1.0 | 0.2–4.0 | 1.00 | 1.0 | 0.2–3.9 | 1.0 |
|
| ||||||||
| AIN 1 1 | 6/19 (32) | 1.0 | 1.0 | |||||
|
| ||||||||
| Number of lesions | 1–2 | 16/32 (50) | 3.4 | 0.9–14 | 0.08 | 3.5 | 0.9–14.7 | 0.08 |
|
| ||||||||
| 3 or more | 5/22 (23) | 1.0 | 1.0 | |||||
|
| ||||||||
| HIV status | HIV-positive | 12/35 (34) | 0.6 | 0.2–2.1 | 0.51 | |||
| HIV-negative | 9/19 (47) | 1.0 | ||||||
|
| ||||||||
| HAART status2,3 | HAART | 8/22 (36) | 1.3 | 0.2–7.6 | 1.00 | |||
| No HAART | 4/13 (31) | 1.0 | ||||||
|
| ||||||||
| CD4+ level at first visit 3 | >200/mL | 10/29 (35) | 1.6 | 0.1–91 | 1.00 | |||
| <200/mL | 1/4 (25) | 1.0 | ||||||
|
| ||||||||
| HIV viral load at first visit 3 | <4000/mL | 10/25 (40) | ∞ | 0.74–∞ | 0.10 | |||
|
| ||||||||
| >4000/mL | 0/7 (0) | 1.0 | ||||||
1
AIN, anal intraepithelial neoplasia
2
HAART, highly active antiretroviral therapy
3
HIV-positive subjects only